Entering text into the input field will update the search result below

Regeneron clarifies canakinumab royalty deal with Novartis

Jun. 22, 2017 10:52 AM ETNovartis AG (NVS) StockBy: Douglas W. House, SA News Editor5 Comments
  • Novartis' (NYSE:NVS +4.4%) announcement of positive late-stage results for canakinumab in reducing CV risk prompts Regeneron Pharmaceuticals (REGN +2.5%) to issue a statement clarifying its royalty rights to the candidate if approved for sale as specified in their 2009 agreement.
  • Regeneron's royalty starts at 4% and ramps to 15% when annual sales of canakinumab exceed $1.5B.
  • Novartis currently markets canakinumab under the brand name ILARIS for the treatment of Juvenile Idiopathic Arthritis.

Recommended For You

About NVS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
NVS--
Novartis AG